- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06270706
Uno studio di fase 1 su PLN-101095 negli adulti con tumori solidi avanzati o metastatici
Uno studio di fase 1a/1b multicentrico, in aperto, di incremento/espansione della dose per valutare la sicurezza, la tollerabilità, la farmacocinetica e le prove preliminari dell'attività antitumorale di PLN-101095 in monoterapia e in combinazione con pembrolizumab in partecipanti adulti con tumori solidi avanzati o metastatici Che hanno una progressione della malattia durante il trattamento con Pembrolizumab
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.
The study will consist of 2 main parts:
- Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration
- Part 2: Dose-expansion cohorts using Simon's 2-stage design
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Pliant Therapeutics Medical Monitor
- Numero di telefono: clintrials@pliantrx.com
- Email: clintrials@pliantrx.com
Luoghi di studio
-
-
Barcelona
-
Barcelona, Barcelona, Spagna, 08023
- Reclutamento
- Hospital Universitari Quirónsalud (NEXT Barcelona)
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spagna, 08023
- Reclutamento
- START Barcelona - Hospital HM Nou Delfos
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
Barcelona, Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitari Vall d'Hebron - VHIO
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
La Rioja
-
Logroño, La Rioja, Spagna, 26006
- Reclutamento
- START Center for Cancer Research - La Rioja
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Madrid
-
Madrid, Madrid, Spagna, 28040
- Reclutamento
- START Madrid - Hospital Universitario Fundación Jiménez Díaz
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
Madrid, Madrid, Spagna, 28050
- Reclutamento
- START Madrid - Centro Integral Oncológico Clara Campal
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Pozuelo de Alarcón
-
Madrid, Pozuelo de Alarcón, Spagna, 28223
- Reclutamento
- University Hospital Quironsalud Madrid (NEXT Madrid)
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06511
- Completato
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20007
- Reclutamento
- Georgetown University Medical Center
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Winship Cancer Institute of Emory University
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49546
- Reclutamento
- South Texas Accelerated Research Therapeutics (START)
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University Medicine
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
New Jersey
-
East Brunswick, New Jersey, Stati Uniti, 08816
- Reclutamento
- START New Jersey
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
New Brunswick, New Jersey, Stati Uniti, 08901
- Reclutamento
- Rutgers Cancer Institute of New Jersey
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
New York
-
Lake Success, New York, Stati Uniti, 11042
- Reclutamento
- START New York Long Island LLC
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
North Carolina
-
Wilson, North Carolina, Stati Uniti, 27893
- Reclutamento
- Carolina Cancer Research Center
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Reclutamento
- Avera Medical Group
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Tennessee Oncology
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Texas
-
Austin, Texas, Stati Uniti, 78758
- Reclutamento
- NEXT Austin
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- START Center for Clinical Research
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- University of Texas MD Anderson Cancer Center
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
Houston, Texas, Stati Uniti, 77054
- Reclutamento
- NEXT Houston
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- UT Health San Antonio's Mays Cancer Center
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Utah
-
West Valley City, Utah, Stati Uniti, 84119
- Reclutamento
- START Mountain Region
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Inova Schar Cancer Institute
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- NEXT Virginia
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Washington
-
Edmonds, Washington, Stati Uniti, 98026
- Reclutamento
- Swedish Cancer Institute Medical Oncology
-
Contatto:
- Pliant Therapeutics Medical Monitor
- Email: clintrials@pliantrx.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Has histologically or cytologically confirmed advanced or metastatic solid tumor
- Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
- Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
- Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
- At least 1 measurable lesion, as defined by RECIST v1.1
- Estimated survival of ≥3 months
- Have adequate bone marrow and organ function.
- A female participant is eligible to participate if she is not pregnant, not breastfeeding
Exclusion Criteria:
- Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
- Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
- Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
- Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has known active CNS metastases (brain and/or leptomeningeal metastases)
- Has significant cardiac disease
- Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
- Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part 1 Dose Escalation - 250 mg BID
Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Sperimentale: Part 1 Dose Escalation - 500 mg BID
PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Sperimentale: Part 1 Dose Escalation - 1000 mg BID
PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Sperimentale: Part 1 Dose Escalation - 1000 mg TID
PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Sperimentale: Part 1 Dose Escalation - 2000 mg BID
PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Sperimentale: Part 2 Dose Expansion - NSCLC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Sperimentale: Part 2 Dose Expansion - ccRCC
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC) |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
|
Sperimentale: Part 2 Dose Expansion - TMB-high solid tumors
PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors |
PLN-101095 250 mg BID PLN-101095 500 mg BID PLN-101095 1000 mg BID PLN-101095 1000 mg TID PLN-101095 2000 mg BID PLN-101095 Pembrolizumab (KEYTRUDA) 200 mg IV Q3W |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Lasso di tempo: First dose to 35 days
|
Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications. |
First dose to 35 days
|
|
Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2
Lasso di tempo: Day 1 until 16 weeks after end of study treatment regimen
|
Proportion of participants with treatment-emergent adverse events and serious adverse events. |
Day 1 until 16 weeks after end of study treatment regimen
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Lasso di tempo: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants achieving confirmed iPR or iCR per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
|
Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Lasso di tempo: First dose to disease progression or death from any cause, whichever occurs first.
|
Proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1. |
First dose to disease progression or death from any cause, whichever occurs first.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Lasso di tempo: Day 14, 0 to up to 12 hours
|
Maximum drug concentration (Cmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Lasso di tempo: Day 14, 0 to up to 12 hours
|
Time to Cmax (Tmax) |
Day 14, 0 to up to 12 hours
|
|
PK of PLN-101095 monotherapy in Parts 1 and 2
Lasso di tempo: Day 14, 0 to up to 12 hours
|
Area under the concentration-time curve (AUC0-τ) |
Day 14, 0 to up to 12 hours
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Lasso di tempo: First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
Duration of response (DOR) for objective responders |
First objective response (CR or PR) to disease progression or death from any cause, whichever occurs first
|
|
Duration of anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2
Lasso di tempo: First dose to progression or death from any cause, whichever occurs first
|
Time on treatment (TOT) for objective responders |
First dose to progression or death from any cause, whichever occurs first
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Pliant Therapeutics Medical Monitor, Pliant Therapeutics, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Carcinoma uroteliale
- Immunoterapia
- Pembrolizumab
- Melanoma
- Cancro colorettale
- Tumore endometriale
- Carcinoma polmonare non a piccole cellule (NSCLC)
- Colangiocarcinoma
- Tumori solidi avanzati Cancro
- Cistifellea
- Carcinoma ovarico
- Cancro al seno triplo negativo (TNBC)
- Carcinoma anale
- Carcinoma a cellule renali a cellule chiare (CCRCC)
- Carcinoma delle vie biliari (BTC)
- Carcinoma Squamoso della Testa e del Collo (HNSCC)
- Tumori con alto carico mutazionale tumorale (TMB)
- Tumori con basso carico di mutazioni tumorali (TMB-low)
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Processi patologici
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie intestinali
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Neoplasie intestinali
- Malattie del retto
- Malattie uterine
- Malattie genitali, femmina
- Malattie polmonari
- Neoplasie delle ghiandole endocrine
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Malattie del colon
- Processi neoplastici
- Neoplasie polmonari
- Malattie ovariche
- Malattie annessiali
- Neoplasie genitali, femmina
- Disturbi gonadici
- Malattie della pelle
- Malattie del seno
- Neoplasie urologiche
- Carcinoma
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Neoplasie renali
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Neoplasie uterine
- Tumori neuroendocrini
- Nevi e melanomi
- Neoplasie cutanee
- Neoplasie mammarie
- Malattie dell'ano
- Neoplasie Rettali
- Condizioni patologiche, segni e sintomi
- Malattie della pelle e del tessuto connettivo
- Neoplasie colorettali
- Neoplasie ovariche
- Metastasi neoplastica
- Carcinoma, cellule renali
- Carcinoma, polmone non a piccole cellule
- Colangiocarcinoma
- Melanoma
- Neoplasie mammarie triplo negativo
- Neoplasie endometriali
- Carcinoma, cellula di transizione
- Neoplasie dell'ano
- pembrolizumab
Altri numeri di identificazione dello studio
- PLN-101095-ONC-101
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .